Group 1 - The core point of the article is that Yingkang Life plans to acquire a 51% stake in Changsha Kexin Oncology Hospital for 357 million yuan, which will allow it to gain control and consolidate the hospital's financials [2] - Changsha Kexin, established in 2015, is a tertiary oncology specialty hospital with 420 beds and reported revenue of 273 million yuan and net profit of 33.43 million yuan for the first three quarters of 2024 [2] - The hospital has committed to achieving net profits of no less than 57 million yuan, 58 million yuan, and 60 million yuan for the years 2025 to 2027, totaling 175 million yuan, which represents a significant increase of 73%-82% compared to historical performance [2] Group 2 - The acquisition is part of Yingkang Life's "1+n" strategy, which aims to establish a regional center hospital that supports multiple satellite hospitals [2] - Currently, Yingkang Life operates three owned hospitals and seven managed institutions, with projected medical service revenue of 1.192 billion yuan in 2024, where oncology revenue is expected to account for 31.9% [3] - Following the acquisition, Yingkang Life's total assets are reported at 3.537 billion yuan, with a debt ratio of 29.93%, indicating that total liabilities may increase post-acquisition [3]

星标 ★ IPO日报 精彩文章第一时间推送 背靠海尔集团公司（下称"海尔集团"），上市公司盈康生命科技股份有限公司（下称"盈康生命"，300143.SZ）即将迎来第四家自有医院。 近期，盈康生命发布公告，拟以3.57亿元现金收购长沙珂信肿瘤医院有限公司（下称"长沙珂信"）51%股权。在交易完成后，长沙珂信将成为盈康生命下 属控股子公司，纳入公司合并报表范围。 制图：佘诗婕 扩张医疗版图 近年来，海尔集团开始积极布局医疗健康领域。 据悉，苏州广慈肿瘤医院是一所二级甲等肿瘤医院。 除了上述3家医院，盈康生命旗下还有上海永慈康复医院等7家托管机构。 此次"拿下"长沙珂信这家三级肿瘤医院，也可以说是符合盈康生命战略的重要落子。盈康生命早年提出"1+n"战略（即1家区域中心医院带动多家卫星医 院），通过并购与托管加速区域医疗中心布局。 对于这次并购，盈康生命表示，并购标的肿瘤医疗服务收入占比高，将有力强化公司在肿瘤特色医疗领 域的战略布局。 增值率1429.99% 据了解，此前盈康生命就已与湖南珂信健康产业集团有限公司（下称"珂信集团"）、长沙珂信签署相关协议。根据协议，珂信集团向盈康生命承诺，长沙 珂信2025年度、 ...